Auddia raises bridge note caps for merger targets, LT350 limit up to $1.9 million
On October 16, 2026, Auddia amended its senior unsecured bridge notes with Thramann Holdings and three target companies controlled by CEO Dr. Jeffrey Thramann, raising the maximum amount Auddia may fund under each note. The notes provide interim working capital while the Merger Agreement with McCarthy Finney, Inc. is pending, and no further funding will be made if that agreement is terminated. Shareholders may want to note that Auddia's potential funding commitments to related parties increased, and the merger still requires Auddia stockholder approval.
Key points
- The October 16, 2026 amendment raised maximum funding caps to $420,000 for Thramann Holdings, $1.9 million for LT350, $900,000 for Influence Healthcare and $85,000 for Voyex.
- The original July 17, 2026 caps were $360,000, $400,000, $590,000 and $50,000, respectively.
- Advances above $50,000 require approval from Auddia's Audit Committee, and funding is made in tranches as mutually agreed.
- The merger is subject to closing conditions, including approval by Auddia stockholders; McCarthy Finney would trade as MCFN after closing.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.